HOOK - HOOKIPA Pharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.21
+0.55 (+5.69%)
As of 12:30PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close9.66
Open9.92
Bid10.21 x 1000
Ask10.47 x 1300
Day's Range9.92 - 10.31
52 Week Range5.80 - 14.37
Volume20,070
Avg. Volume75,317
Market Cap261.832M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.86
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
  • GlobeNewswire

    HOOKIPA Announces Issuance of US and European Patents

    NEW YORK and VIENNA, Austria, Aug. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers, today announced that both the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued patents covering HOOKIPA’s proprietary replicating arenavirus technology (TheraT®). The patents (US Patent No. 10,722,564 and European Patent No. 3218504) are granted to the University of Geneva. HOOKIPA has exclusively licensed these patents from the University. The patent claims cover current product candidates based on HOOKIPA’s replicating arenavirus platform technology (TheraT®), including the Company’s lead oncology product candidates HB-201 and HB-202. These programs are currently in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers.In addition to the replicating arenavirus platform patents, the USPTO recently granted a patent (US Patent No. 10,669,315) specifically related to HOOKIPA’s HB-201 and HB-202 product candidates, which are two different replicating arenavirus-based vectors encoding the same E7/E6 fusion protein. The patent protection for HB-201 and HB-202 conferred by these platform and product-specific patents extends to 2037 in the United States and 2035 in Europe (not taking into account potential Patent Term Extension or Supplementary Protection Certificates)."The newly issued patents provide general, long-term patent protection for our arenavirus technology and related oncology programs. The combination of broad patents on our arenavirus platform and specific patents on product candidates underpin the commercial potential of the therapies we are developing,” said Joern Aldag, HOOKIPA’s Chief Executive Officer.About Replicating Arenavirus Technology (TheraT®) HOOKIPA’s proprietary and patented replicating arenavirus technology induces powerful immune responses. HOOKIPA’s replicating arenavirus constructs are engineered to be specific for antigens of choice. Arenaviruses have a natural ability to evade neutralization, enabling repeated intravenous delivery.The replicating arenavirus platform is able to direct more than 50% of a mouse’s T cells to focus on a single target of choice. In various animal models, immunization with HOOKIPA’s replicating arenavirus resulted in elimination of a primary tumor and metastasis and provided long-term protection against a cancer re-challenge months after primary treatment. The Company believes that its arenavirus-based treatments are more potent immunotherapies than alternative therapeutic modalities.HOOKIPA’s lead oncology programs, HB-201 and HB-202 for the treatment of Human Papillomavirus 16-positive cancers, are both based on its replicating arenavirus platform.About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body’s immune system.HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.Find out more about HOOKIPA online at www.hookipapharma.com.HOOKIPA Forward Looking StatementsCertain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results for HB-101 and other programs, and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA’s ability to achieve the milestones under the agreement with Gilead. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended March 31, 2020 which is available on the Security and Exchange Commission’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com. Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.For further information, please contact:MediaInvestors Nina WaibelMatt Beck Senior Director - CommunicationsExecutive Director - Investor Relations nina.waibel@hookipapharma.commatthew.beck@hookipapharma.com    Media enquiries  Instinctif Partners  hookipa@instinctif.com  +44 (0)20 7457 2020

  • Could The HOOKIPA Pharma Inc. (NASDAQ:HOOK) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The HOOKIPA Pharma Inc. (NASDAQ:HOOK) Ownership Structure Tell Us Something Useful?

    A look at the shareholders of HOOKIPA Pharma Inc. (NASDAQ:HOOK) can tell us which group is most powerful. Institutions...

  • GlobeNewswire

    HOOKIPA Announces Positive Phase 2 Interim Safety and Immunogenicity Results for its CMV Vaccine Candidate HB‑101

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced positive interim results on its prophylactic Cytomegalovirus (CMV) vaccine candidate HB‑101. HB‑101 is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in patients receiving a kidney transplant from a live donor.

  • GlobeNewswire

    HOOKIPA Announces Changes to its Board of Directors – Resignation of Sander van Deventer

    NEW YORK and VIENNA, Austria, June 19, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Announces FDA Clearance of its IND Application for HB-202/201 Clinical Trial to Treat HPV-Positive Cancers

    HOOKIPA Pharma Inc. (HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for HB-202. This IND allows HOOKIPA to initiate an additional arm in its Phase 1/2 clinical trial for HB-201 (NCT04180215) for the treatment of Human Papillomavirus 16-positive (HPV 16+) cancers. With the IND clearance of HB-202, HOOKIPA will be able to examine not only the safety and efficacy of HB-201 alone but also HB-201 in combination with HB-202 as an alternating two-vector therapy.

  • Hedge Funds Are Selling HOOKIPA Pharma Inc. (HOOK)
    Insider Monkey

    Hedge Funds Are Selling HOOKIPA Pharma Inc. (HOOK)

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

  • Why HOOKIPA (HOOK) Stock Might be a Great Pick
    Zacks

    Why HOOKIPA (HOOK) Stock Might be a Great Pick

    HOOKIPA (HOOK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • GlobeNewswire

    HOOKIPA Pharma to Present at Jefferies Virtual Healthcare Conference

    NEW YORK and VIENNA, Austria, May 26, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • HOOKIPA Pharma Inc. (NASDAQ:HOOK) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
    Simply Wall St.

    HOOKIPA Pharma Inc. (NASDAQ:HOOK) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

    As you might know, HOOKIPA Pharma Inc. (NASDAQ:HOOK) recently reported its first-quarter numbers. It wasn't the...

  • HOOKIPA Pharma Inc (HOOK) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    HOOKIPA Pharma Inc (HOOK) Reports Q1 Loss, Misses Revenue Estimates

    HOOKIPA Pharma Inc (HOOK) delivered earnings and revenue surprises of -10.26% and -15.13%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    HOOKIPA Pharma Reports First Quarter 2020 Financial Results and Provides a Corporate Update

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its financial results and corporate update for the first quarter ended March 31, 2020. For HB-101, although enrollment of kidney transplant patients is currently hampered by the impact of COVID-19, we expect to report preliminary safety and immunogenicity data in July 2020 and efficacy data by the end of 2020, roughly at the same time we expect to report preliminary safety and efficacy for HB-201. HOOKIPA’s VaxWave®-based prophylactic Cytomegalovirus (CMV) vaccine candidate, HB‑101, is in a randomized, double‑blinded Phase 2 clinical trial in patients awaiting kidney transplantation who are at risk for CMV-associated complications post-transplant.

  • Will HOOKIPA Pharma Inc (HOOK) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will HOOKIPA Pharma Inc (HOOK) Report Negative Earnings Next Week? What You Should Know

    HOOKIPA Pharma Inc (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    HOOKIPA Pharma To Report First Quarter 2020 Financial Results on May 14, 2020

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it will release financial results for the first quarter ended March 31, 2020 before the market opens on Thursday, May 14, 2020. The Company will not be conducting a conference call in conjunction with this earnings release. Until otherwise noted, the Company will only conduct an earnings conference call in conjunction with its fourth quarter earnings releases.

  • GlobeNewswire

    HOOKIPA Pharma to Present at Upcoming Conferences in May

    NEW YORK and VIENNA, Austria, April 29, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the publication in The Journal of Infectious Diseases of the Phase 1 results of HOOKIPA's VaxWave®-based prophylactic Cytomegalovirus (CMV) vaccine candidate HB-101, which is currently in a Phase 2 clinical trial. The paper concludes that HB-101 was well tolerated and induced CMV-specific poly-functional CD8 T cell and neutralizing antibody responses in nearly all subjects. The absence of vector-neutralizing antibody responses allowed all CMV antigen-specific immune responses to be increased in a statistically significant manner upon repeated vaccine re-administration, which should facilitate additional booster vaccinations.

  • Did Changing Sentiment Drive HOOKIPA Pharma's (NASDAQ:HOOK) Share Price Down By 43%?
    Simply Wall St.

    Did Changing Sentiment Drive HOOKIPA Pharma's (NASDAQ:HOOK) Share Price Down By 43%?

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...

  • GlobeNewswire

    HOOKIPA Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update

    NEW YORK and VIENNA, Austria, March 19, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • ACCESSWIRE

    HOOKIPA Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2020 / HOOKIPA Pharma, Inc. (NASDAQ:HOOK) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, 2020 at 8:00 ...

  • GlobeNewswire

    HOOKIPA Pharma To Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 19, 2020

    NEW YORK and VIENNA, Austria, March 10, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Pharma to Present at SVB Leerink 9th Annual Global Healthcare Conference

    NEW YORK and VIENNA, Austria, Feb. 18, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • Is HOOKIPA Pharma (NASDAQ:HOOK) Using Debt In A Risky Way?
    Simply Wall St.

    Is HOOKIPA Pharma (NASDAQ:HOOK) Using Debt In A Risky Way?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

    NEW YORK and VIENNA, Austria, Jan. 06, 2020 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.

  • GlobeNewswire

    HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive Cancers

    HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that the first patient has been dosed in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology. In addition to strong immunogenicity, HOOKIPA observed robust anti-tumor activity in mouse models.

  • Hedge Funds Have Never Been This Bullish On HOOKIPA Pharma Inc. (HOOK)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On HOOKIPA Pharma Inc. (HOOK)

    Is HOOKIPA Pharma Inc. (NASDAQ:HOOK) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • GlobeNewswire

    HOOKIPA Pharma to Present at Piper Jaffray 31st Annual Healthcare Conference

    NEW YORK and VIENNA, Austria, Nov. 25, 2019 -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious.